Phase 2Status unknown
Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer
A Single-arm, Open-lable, Multicenter, Phase II Clinical Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer
- Sponsor
- Taizhou HoudeAoke Biomedical Co., Ltd. (Industry)
- Enrollment
- 46 planned
- Conditions
- Small-cell Lung Cancer
- Interventions
- LP002; Carboplatin; Etoposide
- Ages
- adults, older adults
- Registry
- NCT04740021
Full record on ClinicalTrials.gov
From the registry
LP002 is a highly selected recombinant humanized anti-PD-L1 monoclonal antibody. This is a single-arm, multicenter study to evaluate the efficacy and safety of LP002 in combination with chemotherapy in patients with extensive stage samll cell lung cancer.
Primary outcomes
- Progression-free Survival (PFS)
History
Study completion
Primary completion
Registered
Started